Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia

Starting soon · Phase 2

Conditions studied: Bacteremia Due to Staphylococcus Aureus

In brief

The CLOPI-SNAP study is a randomized, multicenter, open-label clinical trial embedded within the SNAP (NCT 05137119) research platform. It constitutes a sub-study added to the core protocol for patients suffering Staphylococcus aureus bacteremia (SAB).

Key facts

Study ID

NCT07384702

Run by

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

People needed

230

Starts

2026-06-01

Expected to finish

2030-06-01

Last updated by the study team

2026-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• To be eligible, patients must meet the same criteria as those of the general SNAP platform, as well as the domain-specific criteria:
• Microbiological isolation: Presence of Staphylococcus aureus complex in at least one blood culture.
• Hospitalization status: The patient must be admitted to a participating hospital at the time of eligibility assessment.
• Time window: Eligibility assessment must be completed within 72 hours after collection of the initial blood culture.

You may not qualify if…

• General Medical and Safety Factors:
• Allergies: Known hypersensitivity to thienopyridines (clopidogrel, prasugrel, ticlopidine).
• Clinical status: Inability to tolerate or take oral medications, and severe hepatic impairment (Child-Pugh Class C).
• Pregnancy: Pregnant or breastfeeding women.
• High Risk of Bleeding or Hematologic Disorders:
• Active or recent bleeding: Significant bleeding or invasive procedures within the previous 7 days.
• Planned surgeries: Requirement for major surgical intervention within 10 days following study enrollment.
• Coagulation parameters: Platelet count <50,000/mm³ or known coagulation disorders.
• Concomitant medications: Patients already receiving regular aspirin therapy, other P2Y12 inhibitors, or therapeutic-dose anticoagulants (prophylactic-dose heparin is permitted).
• Specific Diagnoses and Clinical Criteria:
• Endocarditis: Confirmed diagnosis or clinical suspicion of bacterial endocarditis. Sources indicate that exclusion of endocarditis is justified because the potential benefit of clopidogrel is expected during early phases of high bacterial burden, whereas bleeding risk increases with prolonged treatment or established deep-seated infections.
• Medical judgment: If the treating clinical team determines that participation in this domain is not in the patient's best interest.

Where it is running

• Hospital General Universitario de Alicante — Alicante, Spain
• H.U. Clinic — Barcelona, Spain
• H.U. Mutua Terrassa — Barcelona, Spain
• Hospital del Mar — Barcelona, Spain
• Hospital Universitario Bellvitge — Barcelona, Spain
• Hospital Universitario de la Santa Creu i Sant Pau — Barcelona, Spain
• Hospital Universitario Vall d'Hebron — Barcelona, Spain
• H.U. Reina Sofía — Córdoba, Spain
• Hospital Universitario San Cecilio — Granada, Spain
• H.U. Jerez de la Frontera — Jerez de la Frontera, Spain
• Hospital Universitario La paz — Madrid, Spain
• Hospital Universitario La Princesa — Madrid, Spain
• Hospital Universitario Ramon y Cajal — Madrid, Spain
• Hospital Universitario Son Espases — Palma de Mallorca, Spain
• Hospital Virgen Macarena — Seville, Spain
• H.U. Virgen del Rocío — Seville, Spain
• Hospital Universitario Virgen de Valme — Seville, Spain
• Hospital Universitario Marqués de Valdecilla — Valdecilla, Spain
• Hospital Universitario Álvaro Cunqueiro — Vigo, Spain
• Hospital Universitario Lozano Blesa — Zaragoza, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.